Researchers at Osaka Metropolitan University have discovered a practical way to detect and fix common labeling errors in ...

Gabapentin has soared in popularity as an alternative to opioids, but research is finding that it isn’t as safe or effective ...

When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a ...

BeOne Medicines (ONC) announced an update on their ongoing clinical study.

US rare disease specialist Agios Pharmaceuticals (Nasdaq: AGIO) has won approval for Aqvesme (mitapivat) to treat anemia in adults with alpha- or beta-thalassaemia, covering both ...

BEIJING | Xinhua | From the server racks of a São Paulo university to the trading desks of Dubai, the hum of global ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Despite near-term revenue pressure from upcoming patent expirations, Pfizer’s expanding late-stage pipeline, led by oncology ...

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.